John P. Clancy, M.D.
Dr. John Clancy is Professor of Pediatrics at the University of Cincinnati, Tom Boat Chair in Cystic Fibrosis Clinical and Translational Research, and the Director of Pulmonary Medicine Research at Cincinnati Children’s Hospital. He serves as the Gunner Esiasion / Cincinnati Bell endowed chair. He specializes in cystic fibrosis, airway cellular biology, and CFTR regulation. Dr. Clancy has served in several leadership roles at University of Alabama, Cincinnati Children’s Hospital, and within the international cystic fibrosis community.
Christopher Goss, M.D. MS, FCCP
Dr. Christopher Goss is a Professor of Pediatrics Division of Pulmonary and Critical Care Medicine at the University of Washington Medical Center. His research focuses on assessing predictors of survival in patients with CF and generating mathematical models to predict survival in these patients. Additional areas of interest have included the long-term mechanical ventilation outside of the intensive care unit and the epidemiology of acute respiratory distress syndrome.
In addition to work in pulmonary and critical care epidemiology, he is the Associate Medical Director of the Cystic Fibrosis Therapeutics Development Network, a clinical trials network involving academic medical centers across the nation evaluating new and existing therapies for the treatment of patients with cystic fibrosis.
Steven Rowe, M.D., MSPH
Dr. Steven Rowe is Professor of Pulmonary Medicine and Physiology & Biophysics at the University of Alabama at Birmingham. He currently serves as Director of the UAB CF Transition Clinic for adolescent young adults with cystic fibrosis, and Director of the CFF Therapeutics Development Network, Center for CFTR Detection. Dr. Rowe specializes in developing new treatments for cystic fibrosis, and maintains expertise in the design and conduct of clinical trials targeting the basic CF defect.
Dr. Rowe has an interest in biomarkers of CF, including ion transport and the relation between mucus stasis and inflammation. He also directs an International Mucus Clearance Consortium, including basic and translational scientists charged with improving the mechanistic understanding of the mucus clearance defect in cystic fibrosis, and novel means to monitor the process.
Dutch VanDevanter, M.D.
Dr. Dutch VanDevanter is an Adjunct Associate Professor of Pediatrics at Case Western Reserve University. He has extensive experience in CF-related research, clinical design, safety pharmacology, FDA drug development and pulmonary medicine. He is a key contributor to the design and implementation of the Standardized Treatment of Pulmonary Exacerbations (STOP) study which is examining current physician treatment practices and patient outcomes for pulmonary exacerbations.